anonymous
Guest
anonymous
Guest
Only been here for 3 IC cycles but observations:
-Amgen collects very little data-they just trust IQVIA and don't go out and purchase additional data
-Very, very inconsistent. Data points pop up and out of the data capture constantly
-Little transparency - why can't I have my baseline early in quarter and have it not be manipulated up as the quarter goes along? Simply tell me my baseline and let me work towards beating it.
-DOT isn't a good measure if we are trying to grow something. Pay me on TRX. I can use NBRX as a guide, but TRX captures more of what's going on.
Please fix these fundamental flaws and stop trusting India for everything. ZS is wrong about 80% of the time.
-Amgen collects very little data-they just trust IQVIA and don't go out and purchase additional data
-Very, very inconsistent. Data points pop up and out of the data capture constantly
-Little transparency - why can't I have my baseline early in quarter and have it not be manipulated up as the quarter goes along? Simply tell me my baseline and let me work towards beating it.
-DOT isn't a good measure if we are trying to grow something. Pay me on TRX. I can use NBRX as a guide, but TRX captures more of what's going on.
Please fix these fundamental flaws and stop trusting India for everything. ZS is wrong about 80% of the time.